Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression. — From Psychiatric Times articles Read More
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT